Patients with hypertrophic cardiomyopathy have clinical, logistical, and emotional needs that had previously lacked attention and a coordinated approach. The United States-based HCMA recognized Center of Excellence model coupled with strong patient education, support and advocacy services can serve as a model for other nations. Patients benefit from peer support and high-volume HCM care.
OmmenSRMitalSBurkeMA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Circulation2020; 142: e558–e631.
Kim LKSwaminathan RVLooser P, et al. Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy US Nationwide Inpatient Database,2003–2011.
7.
MaronBJRowinEJCaseySA, et al. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality shaped by 50 years of clinical research and practice, JAMA Cardiol2016; 1: 98–105. doi:10.1001/jamacardio.2015.0354
8.
AlexanderTNikolaosPEricaS, et al. Access and outcomes among hypertrophic cardiomyopathy patients in a large integrated health system, J Am Heart Assoc2020; 9: e014095.
9.
MaronBJRobertsW. The father of septal myectomy for obstructive HCM, Who also had HCM: The unbelievable story, J Am Coll Cardiol. 2016: 21; 67(24): 2900-3 2000–2003
